

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization

International Bureau



(10) International Publication Number

WO 2017/175116 A1

(43) International Publication Date

12 October 2017 (12.10.2017)

WIPO | PCT

(51) International Patent Classification:

A61N 1/32 (2006.01) A61N 1/40 (2006.01)

(21) International Application Number:

PCT/IB2017/051898

(22) International Filing Date:

4 April 2017 (04.04.2017)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/317,985 4 April 2016 (04.04.2016) US

(72) Inventor; and

(71) Applicant : GILADI, Moshe [IL/IL]; Ein Hatchelet Street, P.B. 92, 40691 Moshav Herut (IL).

(72) Inventor: SHNAIDERMAN, Rosa; Aharon Rosenfeld Street 17/12, 35012 Haifa (IL).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,

BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: REDUCING MOTILITY OF CANCER CELLS USING TUMOR TREATING FIELDS (TTFIELDS)




FIG. 7

(57) Abstract: The spreading of cancer cells in a target region can be inhibited by imposing a first AC electric field in the target region for a first interval of time, with a frequency and amplitude selected to disrupt mitosis of the cancer cells; and imposing a second AC electric field in the target region for a second interval of time, with a frequency and the amplitude selected to reduce motility of the cancer cells. The amplitude of the second AC electric field is lower than the amplitude of the first AC electric field.

WO 2017/175116 A1

## REDUCING MOTILITY OF CANCER CELLS USING TUMOR TREATING FIELDS (TTFIELDS)

### CROSS REFERENCE TO RELATED APPLICATIONS

[0001] This Application claims the benefit of US Provisional Application 62/317,985, filed April 4, 2016, which is incorporated herein by reference in its entirety.

### BACKGROUND

[0002] TTFIELDS are an effective and FDA approved approach for treating tumors. Treatment using TTFIELDS involves the continuous, noninvasive application of low intensity, intermediate frequency, alternating electric fields to a target region that includes the tumor. Previous investigations have shown that TTFIELDS disrupt of microtubules and septin filaments, both of which govern key roles in mitosis.

[0003] Novocure's Optune® system is the current state of the art for treating glioblastoma using TTFIELDS. Optune® uses a set of electrodes (also referred to as transducer arrays) that are positioned on a patient's body in the vicinity of the tumor. The Optune® field generator unit applies AC signals to those electrodes so as to induce an AC electric field in a target region that includes the tumor.

[0004] The Optune® system works best when the strength of the AC electric field in the tumor is > 1 V/cm RMS, and increasing the field strength to between 2 and 3 V/cm RMS generally provides improved results. But thermal considerations often limit the strength of the AC electric field that can be delivered to the target region. More specifically, because the patient's skin must be protected from overheating, the Optune® system detects the temperature beneath the transducer arrays, and sometimes reduces the strength of the electric field to keep that temperature from exceeding 41° C. Unfortunately, the safety and comfort

benefits provided by this temperature control tactic are accompanied by a drawback: the reduced-strength field is less effective at disrupting mitosis than a full-strength field.

## SUMMARY OF THE INVENTION

**[0005]** One aspect of the invention is directed to a first method of inhibiting spreading of cancer cells in a target region. This method comprises (a) imposing a first AC electric field in the target region for a first interval of time, the first AC electric field having a first frequency and a first amplitude. The first frequency and the first amplitude are selected so that the first AC electric field disrupts mitosis of the cancer cells. This method also comprises (b) imposing a second AC electric field in the target region for a second interval of time, the second AC electric field having a second frequency and a second amplitude. The second frequency and the second amplitude are selected so that the second AC electric field reduces motility of the cancer cells, and the second amplitude is lower than the first amplitude. This method also comprises continuously repeating step (a) and step (b) in an alternating sequence during a course of treatment.

**[0006]** In some embodiments of the first method, the second amplitude is less than 75% of the first amplitude. Optionally, in these embodiments, the first interval of time is less than 5 seconds, and the second interval of time is less than 5 seconds. The course of treatment may a duration of at least 12 hours.

**[0007]** In some embodiments of the first method, the second frequency and the first frequency are different. In some embodiments of the first method, the first frequency is 200 kHz  $\pm$  10% and the second frequency is 300 kHz  $\pm$  10%.

**[0008]** In some embodiments, the first method further comprises the step of administering a compound that inhibits cell motility during the course of treatment. In some of these embodiments, the compound comprises Bumetanide.

**[0009]** In some embodiments of the first method, the second amplitude is at least 0.6 V/cm RMS.

**[0010]** In some embodiments of the first method, the second amplitude is less than 75% of the first amplitude, the second frequency and the first frequency are different, the first interval of time is less than 5 seconds, the second interval of time is less than 5 seconds, and the second amplitude is at least 0.6 V/cm RMS. Optionally in these embodiments, the first frequency is  $200 \text{ kHz} \pm 10\%$  and the second frequency is  $300 \text{ kHz} \pm 10\%$ .

**[0011]** In some embodiments of the first method, the first AC electric field is imposed in the target region in a first direction for a first portion of the first interval of time, the first AC electric field is imposed in the target region in a second direction for a second portion of the first interval of time, and an angle between the first direction and the second direction is between  $60^\circ$  and  $90^\circ$ . In some of these embodiments, the second AC electric field is imposed in the target region in the first direction for a first portion of the second interval of time, and the second AC electric field is imposed in the target region in the second direction for a second portion of the second interval of time. In some of these embodiments, the second amplitude is less than 75% of the first amplitude. In some of these embodiments, the second frequency and the first frequency are different, the first interval of time is less than 5 seconds, and the second interval of time is less than 5 seconds.

**[0012]** In some embodiments of the first method, a direction of the first AC electric field is changed during at least some of the repeating steps, and a direction of the second AC electric field is changed during at least some of the repeating steps. In some of these embodiments, the second amplitude is less than 75% of the first amplitude. In some of these embodiments, the second frequency and the first frequency are different, the first interval of time is less than 5 seconds, and the second interval of time is less than 5 seconds.

**[0013]** Another aspect of the invention is directed to a second method of inhibiting spreading of cancer cells in a target region. This method comprises (a) imposing a first AC electric field in the target region, the first AC electric field having a first frequency and a first amplitude. The first frequency and the first amplitude are selected so that the first AC electric field disrupts mitosis of the cancer cells. This method also comprises (b) imposing a second AC electric field in the target region, the second AC electric field having a second frequency and a second amplitude. The second frequency and the second amplitude are selected so that the second AC electric field reduces motility of the cancer cells. The second frequency and the first frequency are different, and the second amplitude is lower than the first amplitude.

**[0014]** In some embodiments of the second method, the second amplitude is less than 75% of the first amplitude.

**[0015]** Another aspect of the invention is directed to a first apparatus for inhibiting spreading of cancer cells in a target region. This apparatus comprises an AC signal generator having (i) a first controllable output configured to apply an AC voltage across a first set of capacitively coupled electrodes that are positioned in a vicinity of the target region, so as to impose an electric field in the target region in a first direction and (ii) a second controllable output configured to apply an AC voltage across a second set of capacitively coupled electrodes that are positioned in the vicinity of the target region, so as to impose an electric field in the target region in a second direction. This apparatus also comprises a controller configured to (a) control the first controllable output so that a first AC signal is generated for a first interval of time, the first AC signal having a first frequency and a first amplitude. The first frequency and the first amplitude are selected to impose an electric field that disrupts mitosis of the cancer cells. The controller is also configured to (b) control the first controllable output so that a second AC signal is generated for a second interval of time, the

second AC signal having a second frequency and a second amplitude. The second frequency and the second amplitude are selected to impose an electric field that reduces motility of the cancer cells, and the second amplitude is lower than the first amplitude. The controller is also configured to (c) control the second controllable output so that a third AC signal is generated for a third interval of time, the third AC signal having a third frequency and a third amplitude. The third frequency and the third amplitude are selected to impose an electric field that disrupts mitosis of the cancer cells. The controller is also configured to (d) control the second controllable output so that a fourth AC signal is generated for a fourth interval of time. The fourth AC signal has a fourth frequency and a fourth amplitude. The fourth frequency and the fourth amplitude are selected to impose an electric field that reduces motility of the cancer cells, and the fourth amplitude is lower than the third amplitude. The controller is also configured to continuously repeat (a) through (d) in an alternating sequence during a course of treatment.

**[0016]** In some embodiments of the first apparatus, the second amplitude is less than 75% of the first amplitude and the fourth amplitude is less than 75% of the third amplitude. In some embodiments of the first apparatus, the second frequency and the first frequency are different, and the fourth frequency and the third frequency are different.

**[0017]** In some embodiments of the first apparatus, the second amplitude is less than 75% of the first amplitude, the fourth amplitude is less than 75% of the third amplitude, the second frequency and the first frequency are different, the fourth frequency and the third frequency are different, the third frequency is the same as the first frequency, the fourth frequency is the same as the second frequency, the first interval of time is less than 5 seconds, the second interval of time is less than 5 seconds, the third interval of time is less than 5 seconds, and the fourth interval of time is less than 5 seconds.

**[0018]** In some embodiments of the first apparatus, the first frequency is 200 kHz ± 10%, the second frequency is 300 kHz ± 10%, the third frequency is 200 kHz ± 10%, and the fourth frequency is 300 kHz ± 10%.

#### BRIEF DESCRIPTION OF THE DRAWINGS

**[0019]** FIG. 1 depicts an arrangement of electrodes in a Petri dish used to conduct some of the experiments described herein.

**[0020]** FIGS. 2A and 2B depicts the results of cell migration rate experiments that studied TTFields' effects on two different cell lines.

**[0021]** FIG. 3 depicts the results of cell invasion experiments that studied TTFields' effects on four different cell lines.

**[0022]** FIG. 4 depicts the results of cell invasion experiments that studied the frequency dependence of TTFields' inhibition of U-87 glioma.

**[0023]** FIG. 5 depicts the results of cell migration rate experiments that studied the directional dependence of TTFields' inhibition of glioma cancer cells.

**[0024]** FIG. 6 depicts the results of cell invasion experiments that compares the efficacy of TTFields to the efficacy of Bumetanide in inhibiting glioma cancer cells.

**[0025]** FIG. 7 depicts an embodiment of the invention that includes a signal generator and electrodes.

**[0026]** FIG. 8 depicts a first sequence of events for the outputs of the signal generator of the FIG. 7 embodiment.

**[0027]** FIGS. 9A and 9B depict additional sequences of events for the outputs of the signal generator of the FIG. 7 embodiment.

## DESCRIPTION OF THE PREFERRED EMBODIMENTS

**[0028]** The ability of glioblastoma cells to invade adjacent brain tissue can make it difficult to control glioblastoma. The development of treatment modalities that hinder glioma cancer cell motility could therefore facilitate disease control.

**[0029]** The inventors have determined that, in addition to having antimitotic effects, TTFields have an impact on other cellular processes that require proper microtubule dynamics. One such process, which has a major impact on glioblastoma progression, is cell motility. This application documents the effects of TTFields on cell motility, including both the migration and invasion properties of glioma cells. This application also describes methods and systems for reducing cell motility by applying TTFields to cancer cells in a target region.

**[0030]** A set of experiments was run to evaluate the effect of TTFields on human glioma cell motility, including the migration and invasion properties of those cells.

**[0031]** The first experiment used scratch wound assays in vitro to determine the effects of TTFields on migration of U-87 MG and A-172 glioma cells. In this experiment, in vitro wound assays were performed using IBIDI culture-inserts. TTFields (200 kHz, 1.75 RMS) were applied using two pairs of electrodes 141-142 and 143-144 that were insulated by a high dielectric constant ceramic ( $\epsilon > 5000$ ) (Exelis, Salt Lake City, Utah). The electrode pairs 141-142 and 143-144 were positioned in the Petri dish 150° perpendicular to each other with the geometry depicted in FIG. 1. The electrodes 141-143 were connected to a modified Novocure Optune® system, which applied the appropriate AC signals to the electrodes 141-143 in order to generate TTFields in the target region. The TTFields changed direction by 90° every 1 second. This was accomplished by (a) applying the AC signal between electrodes 141

and 142 for 1 s, then (b) applying the AC signal between electrodes 143 and 144 for 1 s, and then repeating that (a) + (b) sequence for the course of the experiment. Temperature was measured by thermistors (not shown) incorporated into the dishes 150.

**[0032]** The U-87 MG and A-172 cells were scratched and imaged. Migration was observed in time-lapse series for 24h (Zeiss axio observer; per 10 objective). Phase contrast images were recorded every 12 min. Baseline images of the scratch at 0 hours and cells that migrated into the scratch area 14 hours later were examined, at the same reference points. The obtained images were further evaluated to quantify cell migration rates during wound healing using the Image Pro Premier (Media Cybernetics, USA) software. Quantitative analysis of migration rate was performed, calculated as the total distance that the cells moved from the edge of the scratch toward the mid-center of the scratch as a function of time.

**[0033]** FIGS. 2A and 2B summarize the results of the quantitative analysis for this first experiment. Cell migration rate was significantly reduced in TTFields treated U-87 MG (31%) and A-172 (27%) cell lines, compared with untreated control cells, as seen in FIG. 2A and FIG. 2B, respectively (mean+SEM; \*\*\*p < 0.001 from control group, student's t-test). The experiment was repeated 3 times. These results indicate that TTFields hinder cell migration in different glioma cell lines.

**[0034]** In a second experiment, an invasion assay was performed using a modified Boyden chamber to determine the effects of TTFields on invasion for U-87 MG, A-172, LN-229 and LN-18 cells. Filters (6.4 mm in diameter, 8  $\mu$ m pore size) coated with Matrigel (Corning) were used. TTFields were applied using the Novocure Inovitro system by means of perpendicular pairs of electrodes insulated by a high dielectric constant ceramic (200 kHz, 0.6 V/cm RMS). The geometry of the electrodes for this experiment was similar to the geometry depicted in FIG. 1, and the direction of the field was switched every 1 s (as

described above for the first experiment). Inovitro dishes with extended vertical walls were used to facilitate effective delivery of TTFields through the transwell. The U-87 MG, A-172, LN-229 and LN-18 cells ( $2 \times 10^5$ ) were suspended in serum free DMEM and seeded on the upper compartment of the chamber. The lower compartment contained 10% FBS DMEM. After incubation for 24 hours at 37°C in a 5% CO<sub>2</sub> incubator, the cells that invaded to the bottom filter, were fixed with 4% PFA, stained with 0.5% crystal violet (Sigma) and imaged under inverted microscope (Nikon eclipse TS100; upper panel-control, Lower panel-TTFields treated cells; Objective x10). Quantification of invading cells was performed using ImageJ software (NIH).

**[0035]** FIG. 3 summarizes the results of the quantification for this second experiment. The number of invading cells was significantly reduced in all TTFields treated cell lines: U-87 MG (54%), A-172 (68%), LN-229 (38%) and in LN-18 (55%) compared with untreated control cells (mean+SEM; \*p < 0.05, \*\*p < 0.01, \*\*\*p < 0.001 from control group, student's t-test). These results indicate that TTFields hinder cell invasion in different glioma cell lines. It is noteworthy that duration of this invasion experiments (24 hours) was shorter than the duration (72 hours) that is ordinarily required for the anti-mitotic effect of TTFields. It was also noteworthy that the electric field intensity (i.e., 0.6 V/cm RMS) that caused this reduction in invasion was lower than the electric field intensity (i.e., > 1 V/cm RMS) that is ordinarily required for the anti-mitotic effect of TTFields.

**[0036]** A third experiment was conducted to study the frequency dependence of TTFields' inhibition of U-87 glioma cancer cells invasive potential. A U-87 invasion assay was performed using modified Boyden chamber as described above in connection with the second experiment. TTFields were applied in various frequencies (100, 200, 300, and 400 kHz) using the same nominal intensity of 0.6 V/cm RMS and the same direction switching

described above in connection with the first experiment. After incubation for 24 hours at 37°C in a 5% CO<sub>2</sub> incubator, the cells that invaded to the bottom filter were fixed, imaged and quantified as described above in connection with the second experiment.

**[0037]** FIG. 4 summarizes the results of the quantification for this third experiment. The number of invading cells was reduced (with respect to the control) for all four frequencies of TTFields tested in a frequency dependent manner; and the maximal reduction in the number of invading cells was observed at a frequency of 300 kHz. Perhaps most notably, the frequency that provided the highest reduction in the invasion potential was different from the 200 kHz frequency that provides (based on previous experiments) the highest anti-mitotic effect in U-87 cells.

**[0038]** A fourth experiment was conducted to study the directional dependence of TTFields' inhibition of glioma cancer cells migration. TTFields (200 kHz, 1.75 RMS) were applied using two pairs of electrodes, insulated by a high dielectric constant ceramic ( $\epsilon$  >5000) (Exelis, Salt Lake City, Utah) positioned in the Petri dish. The geometry of the electron pairs was similar to the geometry shown in FIG. 1. In vitro wound assays were performed using IBIDI culture-inserts with 2 inserts placed in each dish, one in parallel with the electric field and one perpendicular to the direction of the electric field. The electrodes were connected to a modified Optune® system that applied AC signals to the electrodes in order to generate the electric field in the various directions required for this experiment. Temperature was measured by thermistors incorporated into the dishes.

**[0039]** A-172 cells were scratched in 2 perpendicular directions and imaged. Migration was observed in time-lapse series for 24h as described. The obtained images were further evaluated to quantify cell migration rates during wound healing using the Image Pro Premier (Media Cybernetics, USA) software. Quantitative analysis of migration rate

calculated as the total distance that the cells moved from the edge of the scratch toward the mid-center of the scratch as a function of time.

**[0040]** FIG. 5 summarizes the results of the quantitative analysis for this fourth experiment. Cell migration rate was significantly reduced in as compared to the control when cells were migrating in parallel (24%) with the electric field, which was similar to the reduction obtained when the TTFields were applied from two different directions and switched every second (27%). Interestingly, TTFields applied from a single direction, perpendicular to the migration course, resulted in the highest reduction in the migration rate (39%) which was significantly higher than the reduction obtained when TTFields were applied in two directions or a single direction in parallel with the course of migration (\*\*p < 0.001 from both groups, student's t-test. The experiment was repeated 3 times). These results indicate that the direction of the applied electric fields have different effect on the migration rates depending on the course of migration.

**[0041]** A fifth experiment was conducted to compare the efficacy of TTFields to the efficacy of Bumetanide in inhibiting glioma cells invasive potential. Bumetanide is a loop diuretic of the sulfamyl category to treat heart failure, and it is known to affect cellular motility. In the brain, bumetanide blocks the NKCC1 cation-chloride co-transporter, and thus decreases internal chloride concentration in neurons. NKCC1 provides the major pathway for Cl<sup>-</sup> accumulation in glioma cells. NKCC1 localizes to the leading edge of invading processes, and pharmacologic inhibition using the loop diuretic bumetanide inhibits in vitro Transwell migration by 25% to 50%.

**[0042]** An invasion assay was performed as described above in connection with the second experiment with some minor modifications. More specifically, U-87 cells (2x10<sup>5</sup>) were suspended in serum free DMEM and seeded in the upper compartment of the chamber.

The lower compartment contained 10% FBS DMEM. Both compartments contained Bumetanide in the concentration of 200  $\mu$ M. TTFields were applied as described above (200 kHz, 0.6 V/cm RMS). After incubation for 24 hours at 37°C in a 5% CO<sub>2</sub> incubator, the cells that invaded to the bottom filter, were fixed, stained with crystal violet, and imaged under inverted microscopes. Quantification of invading cells was performed using ImageJ software (NIH).

**[0043]** FIG. 6 summarizes the results of the quantification for this fifth experiment. The number of invading cells was significantly reduced in cells treated by TTFields (31%) or Bumetanide (34%) applied alone (\*\*p < 0.001 from control group, student's t-test). And notably, the combined treatment using both TTFields and Bumetanide led to a synergistic 61% reduction in the number of invading cells which was significantly higher than the reduction obtained by TTFields or Bumetanide applied alone (\*\*p < 0.001, student's t-test). These results indicate that exposure to low intensities TTFields in combinations with drugs that inhibit cell motility could lead to a synergistic enhanced inhibitory effect on glioma cells invasiveness as compared to either treatment alone. And more specifically, combining TTFields with Bumetanide resulted in a synergistic enhanced efficacy as compared to either treatment alone.

**[0044]** The current version of Novocure's Optune® system generates AC electric fields in a target region at a single frequency, and that frequency is selected in advance to increase the effectiveness of the field at disrupting mitosis of cancer cells within the target region. As indicated above, the Optune® system sometimes reduces the strength of the electric field to prevent overheating of the patient's skin, which renders the field less effective for disrupting mitosis. The embodiments described below take advantage of two outcomes of the second and third experiment described above. More specifically, the

embodiments described below take advantage of the facts that (1) the electric field intensity that is needed to cause a reduction in motility is lower than the electric field intensity that is ordinarily required for the anti-mitotic effect of TTFields; and (2) for at least certain cell lines, the frequency that provided the highest reduction in motility is different from the frequency that provides highest anti-mitotic effect.

**[0045]** FIG. 7 depicts an embodiment of the invention that includes a signal generator 20 and four electrodes 41-44 (also referred to as transducer arrays). The electrodes 41-44 are positioned so that they can induce an electric field in the target region 50. For example, if the target region is a petri dish, the electrodes 41-44 may be positioned in contact with the walls of the Petri dish that contains cancer cells 55. Alternatively, if the target region is a portion of a patient's body, the electrodes 41-44 may be positioned in contact with the patient's skin in the vicinity of a tumor that includes cancer cells 55. The signal generator 20 has two outputs Q1 and Q2. The first output Q1 is connected across electrodes 41 and 42, and the second output Q2 is connected across the electrodes 43 and 44. When the signal generator 20 outputs an AC voltage at output Q1, that voltage will appear across the electrodes 41, 42 and induce an electric field in the target region 50 in a first direction D1. When the signal generator 20 outputs an AC voltage at output Q2, that voltage will appear across the electrodes 43, 44 and induce an electric field in the target region 50 in a second direction D2. Temperature sensors 48 detect the temperature at the electrodes 41-44 and report those temperatures back to a temperature sensor interface 22 contained within the signal generator 20. If the detected temperature is too high, the controller 25 will command the power stage 28 of the signal generator 20 to reduce its output voltage, which will ultimately bring the temperature down.

**[0046]** Note that the description of FIG. 7 in the previous paragraph is very similar to the operation of the current version of the Novocure Optune® system. But the FIG. 7

embodiment is distinguishable from Optune® because the Optune® field generator unit always outputs the same frequency. More specifically, the Optune® field generator unit always outputs a frequency that was preselected based on its anti-mitotic effect on the relevant cancer (i.e., 200 kHz in the context of glioblastoma). In contrast, the FIG. 7 embodiment switches the frequency of its outputs Q1, Q2 between a first frequency that is selected to disrupt mitosis of the cancer cells and a second frequency that is selected to reduce the motility of the cancer cells. This is accomplished in the FIG. 7 embodiment by the controller 25, which outputs appropriate control signals to the power stage 28 in order to control the frequency and amplitude of the outputs Q1 and Q2 as described below in connection with FIGS. 8-9. The controller 25 may be implemented using any of a variety of techniques that will be apparent to persons skilled in the relevant arts. Examples include but are not limited to a microprocessor or microcontroller-based controllers that are programmed to implement the sequences described herein; and hardware timers that generate appropriate control signals to orchestrate the sequences described herein. The hardware implementation of the power stage 28 is configured to respond to the control signals that are generated by the controller 25.

**[0047]** FIG. 8 depicts a first sequence of events for the outputs Q1 and Q2 generated by the power stage 28 under control of the controller 25. In this sequence, the direction of the field is never switched, which means that only one of the outputs of the power stage (i.e. either Q1 or Q2) is necessary, and only one pair of electrodes (i.e., either 41/42 or 43/44) is necessary. The sequence for the lower half of FIG. 8 is as follows: First, between t0 and t1, a first AC electric field at a first frequency that is selected to disrupt mitosis of the cancer cells is imposed in the target region. Then, between t1 and t2, a second AC electric field at a second frequency that is selected to reduce motility of the cancer cells is imposed in the target region. This sequence is then repeated until the course of treatment ends.

**[0048]** In some embodiments, in addition to switching the frequency (as shown in the lower half of FIG. 8), the amplitude of the signal generator' output is also switched in synchrony (as shown in the upper half of FIG. 8). In these embodiments, sequence of events for the outputs generated by the power stage 28 under control of the controller 25 is as follows.

**[0049]** In step (a), a first AC electric field is imposed in the target region for a first interval of time (e.g., the interval between t0 and t1). The first AC electric field has a first frequency and a first amplitude, and the first frequency and the first amplitude are selected so that the first AC electric field disrupts mitosis of the cancer cells. In step (b), a second AC electric field is imposed in the target region for a second interval of time (e.g., the interval between t1 and t2). The second AC electric field has a second frequency and a second amplitude, and the second frequency and the second amplitude are selected so that the second AC electric field reduces motility of the cancer cells. The second amplitude is lower than the first amplitude. These steps (a) and (b) are then continuously repeated in an alternating sequence during a course of treatment. Optionally, additional intervening steps may be added between step (a) and step (b) or between step (b) and step (a). For example, the controller 25 may command the power stage 28 to output a third frequency between one or more instances of step (a) and step (b).

**[0050]** As noted above, the second amplitude (during the anti-motility phase) is lower than the first amplitude (during the anti-mitosis phase). But this is not problematic because the electric field intensity that is needed to cause a reduction in motility is lower than the electric field intensity that is ordinarily required for the anti-mitotic effect of TTFields. And advantageously, the system can rely on the reduced amplitude during the anti-motility phase

to reduce the temperature at the electrodes without reducing the field strength during the anti-mitosis phase (which requires a higher amplitude).

**[0051]** Furthermore, this advantage is compounded by the fact that the temperature rise is proportional to the square of the amplitude. As a result, lowering the amplitude during the anti-motility phase by X % will lower the heating during that phase to  $(1-X)^2$  %. For example, lowering the amplitude from 2 V/cm to 1 V/cm during the anti-motility phase will lower the heating during that phase to  $(1-0.5)^2$  % (i.e., to one quarter of its original value). If we assume that the anti-motility phase and the anti-mitosis phases have the same duration, this modification would reduce the overall heating load to 5/8 of its original value.

**[0052]** In some preferred embodiments, the second amplitude is less than 75% of the first amplitude. Preferably, both the first interval of time and the second interval of time are less than five seconds. This can be important for sustaining the anti-mitosis affect without interruption. Preferably, the course of treatment has a duration of at least 12 hours. In some preferred embodiments, the first frequency and the second frequency are different. In other embodiments, the first frequency and the second frequency could be the same (i.e., for cell lines in which the anti-mitosis frequency coincides with the anti-motility frequency). In some preferred embodiments, the first frequency (i.e., the anti-mitosis frequency) is 200 kHz  $\pm$  10% and the second frequency (i.e., the anti-motility frequency) is 300 kHz  $\pm$  10%. In some preferred embodiments, the second amplitude is at least 0.6 V/cm RMS, in order to maintain the anti-motility effect. Optionally, a compound that inhibits cell motility (e.g., Bumetanide) may be administered during the course of treatment.

**[0053]** In some embodiments, in addition to switching the frequency of the field between a first frequency optimized for disrupting mitosis and a second frequency optimized for reducing motility, the direction of the electric field in the target region can also be

switched between two or more directions. FIGS. 9A and 9B depict two examples in which the direction of the field is switched between the two directions D1 and D2 shown in FIG. 7. The field is generated in the direction D1 when the signal generator 20 generates its output Q1, which is applied between electrodes 41 and 42. The field is generated in the direction D2 when the signal generator 20 generates its output Q2, which is applied between electrodes 43 and 44.

**[0054]** FIG. 9A depicts the sequence of events for the outputs Q1 and Q2 generated by the power stage 28 of the signal generator 20 under control of the controller 25 in one such embodiment. In this sequence, the direction is switched between the two directions D1 and D2 at a rate that is faster than the rate at which the frequency is switched. The sequence here is similar to the sequence described above in connection with FIG. 8 in which both the frequency and the amplitude are switched in synchrony with each other. But in addition to switching the frequency and the amplitude as described above in connection with FIG. 8, the direction of the field is also switched. More specifically, the first AC electric field is imposed in the target region in a first direction for a first portion of the first interval of time (i.e., the first portion of the time between t0 and t1), and the first AC electric field is imposed in the target region in a second direction for a second portion of the first interval of time (i.e., the last portion of the time between t0 and t1). Preferably, the angle between the first direction D1 and the second direction D2 is between 60° and 90°. (Note that all numeric angular ranges used herein are inclusive of the endpoints.)

**[0055]** In some embodiments, in addition to switching the directions during the first interval of time (which corresponds to the anti-mitosis phase), the direction is also be switched during the second interval of time (which corresponds to the anti-motility phase). In these embodiments, the second AC electric field is imposed in the target region in the first

direction for a first portion of the second interval of time (i.e., the first portion of the time between  $t_1$  and  $t_2$ ), and the second AC electric field is imposed in the target region in the second direction for a second portion of the second interval of time (i.e., the last portion of the time between  $t_1$  and  $t_2$ ).

**[0056]** FIG. 9B depicts the sequence of events for the outputs Q1 and Q2 generated by the power stage 28 under control of the controller 25 in another embodiment. In this sequence, the direction is switched between the two directions D1 and D2 at a rate that is slower than the rate at which the frequency is switched. The sequence here is similar to the sequence described above in connection with FIG. 8 in which both the frequency and the amplitude are switched in synchrony with each other. But in addition to the switching of the frequency and the amplitude described above in connection with FIG. 8, the direction of the first AC electric field is changed during at least some of the repeating steps, and the direction of the second AC electric field is also changed during at least some of the repeating steps. In the example of FIG. 9B, the original sequence corresponds to the interval of time between  $t_0$  and  $t_2$ , and that original sequence is repeated during the course of the treatment, with the first repetition occupying the interval of time between  $t_2$  and  $t_4$ . As seen in FIG. 9B, the direction of the fields for both the anti-mitosis stage and the anti-migration stage was switched to D2 during the first repetition with respect to the original sequence.

**[0057]** Note that in the sequences depicted in FIGS. 8-9 above, the anti-mitosis phase and the anti-motility phase are mutually exclusive with respect to time. However, in alternative embodiments, those phases may overlap with each other either partially or completely. An example of such an embodiment would be to implement the following two steps (a) and (b) simultaneously: In step (a), a first AC electric field is imposed in the target region. The first AC electric field has a first frequency and a first amplitude that are selected

so that the first AC electric field disrupts mitosis of the cancer cells. In step (b), a second AC electric field is imposed in the target region. The second AC electric field has a second frequency and a second amplitude that are selected so that the second AC electric field reduces motility of the cancer cells. The second frequency and the first frequency are different, and the second amplitude is lower than the first amplitude. When steps all (a) and (b) are implemented simultaneously, the first and second AC electric fields will add by superposition.

**[0058]** Some embodiments are directed to a method for treating cancer by exposing the primary tumor or its vicinity, metastases, or organs with high probability of metastatic uptake to alternating electric fields at a frequency optimally picked to inhibit the migration or invasion of the tumor cells. At least for certain cell lines, this frequency is significantly different from the frequency required to disrupt mitosis. The field may be delivered using Novocure's Optune® system or the devices described in US patents 7089054, 6868289, and 7706890, which are incorporated herein by reference. It may be used to treat GBM or other types of cancer. The field may be delivered in a preferential direction, and the preferential direction chosen to prevent progression into non-resectable areas, or vital organs.

**[0059]** For different types of cancer, the optimal frequency for inhibiting cell migration of a specific cancer cell type may be determined by culturing the cells (or a cell line that closely resembles the cells of interest) in petri dishes, exposing the cells to alternating electric fields at a given intensity, and at different frequencies, and finding the frequency that has the maximal inhibitory effect on cell migration for this specific cell line. The effect of the electric field may be determined via scratch assays and/or via an invasion assay.

**[0060]** Some embodiments are directed to a method for treating cancer, whereby the tumor is exposed to alternating electric fields containing components at two frequencies: One frequency is the frequency that is optimal to inhibit cell division, and the other frequency optimal to inhibit migration. Note that combining two different frequencies tuned to damage dividing cells is described in US patent 8244345, which is incorporated herein by reference. But here, one of the frequencies is tuned to prevent migration instead. The signals at the different frequencies may be applied sequentially, or they may be combined into a single field. The fields may be delivered in one direction or a plurality of different directions.

**[0061]** While the present invention has been disclosed with reference to certain embodiments, numerous modifications, alterations, and changes to the described embodiments are possible without departing from the sphere and scope of the present invention, as defined in the appended claims. Accordingly, it is intended that the present invention not be limited to the described embodiments, but that it has the full scope defined by the language of the following claims, and equivalents thereof.

## WHAT IS CLAIMED IS:

1. A method of inhibiting spreading of cancer cells in a target region, the method comprising:
  - (a) imposing a first AC electric field in the target region for a first interval of time, the first AC electric field having a first frequency and a first amplitude, wherein the first frequency and the first amplitude are selected so that the first AC electric field disrupts mitosis of the cancer cells;
  - (b) imposing a second AC electric field in the target region for a second interval of time, the second AC electric field having a second frequency and a second amplitude, wherein the second frequency and the second amplitude are selected so that the second AC electric field reduces motility of the cancer cells, and wherein the second amplitude is lower than the first amplitude; and
  - (c) continuously repeating step (a) and step (b) in an alternating sequence during a course of treatment.
2. The method of claim 1, wherein the second amplitude is less than 75% of the first amplitude.
3. The method of claim 2, wherein the first interval of time is less than 5 seconds, and wherein the second interval of time is less than 5 seconds.
4. The method of claim 3, wherein the course of treatment has a duration of at least 12 hours.

5. The method of claim 1, wherein the second frequency and the first frequency are different.
6. The method of claim 1, wherein the first frequency is  $200 \text{ kHz} \pm 10\%$  and the second frequency is  $300 \text{ kHz} \pm 10\%$ .
7. The method of claim 1, further comprising the step of administering a compound that inhibits cell motility during the course of treatment.
8. The method of claim 7, wherein the compound comprises Bumetanide.
9. The method of claim 1, wherein the second amplitude is at least  $0.6 \text{ V/cm RMS}$ .
10. The method of claim 1, wherein the second amplitude is less than 75% of the first amplitude, wherein the second frequency and the first frequency are different, wherein the first interval of time is less than 5 seconds, wherein the second interval of time is less than 5 seconds, and wherein the second amplitude is at least  $0.6 \text{ V/cm RMS}$ .
11. The method of claim 10, wherein the first frequency is  $200 \text{ kHz} \pm 10\%$  and the second frequency is  $300 \text{ kHz} \pm 10\%$ .
12. The method of claim 1, wherein the first AC electric field is imposed in the target region in a first direction for a first portion of the first interval of time, wherein the first AC electric field is imposed in the target region in a second direction for a second portion of the first interval of time, and

wherein an angle between the first direction and the second direction is between 60° and 90°.

13. The method of claim 12, wherein the second AC electric field is imposed in the target region in the first direction for a first portion of the second interval of time, and wherein the second AC electric field is imposed in the target region in the second direction for a second portion of the second interval of time.

14. The method of claim 13, wherein the second amplitude is less than 75% of the first amplitude.

15. The method of claim 14, wherein the second frequency and the first frequency are different, wherein the first interval of time is less than 5 seconds, and wherein the second interval of time is less than 5 seconds.

16. The method of claim 1, wherein a direction of the first AC electric field is changed during at least some of the repeating steps, and wherein a direction of the second AC electric field is changed during at least some of the repeating steps.

17. The method of claim 16, wherein the second amplitude is less than 75% of the first amplitude.

18. The method of claim 17, wherein the second frequency and the first frequency are different, wherein the first interval of time is less than 5 seconds, and wherein the second interval of time is less than 5 seconds.

19. A method of inhibiting spreading of cancer cells in a target region, the method comprising:

(a) imposing a first AC electric field in the target region, the first AC electric field having a first frequency and a first amplitude, wherein the first frequency and the first amplitude are selected so that the first AC electric field disrupts mitosis of the cancer cells;

(b) imposing a second AC electric field in the target region, the second AC electric field having a second frequency and a second amplitude, wherein the second frequency and the second amplitude are selected so that the second AC electric field reduces motility of the cancer cells, wherein the second frequency and the first frequency are different, and wherein the second amplitude is lower than the first amplitude.

20. The method of claim 19, wherein the second amplitude is less than 75% of the first amplitude.

21. An apparatus for inhibiting spreading of cancer cells in a target region, the apparatus comprising:

an AC signal generator having (i) a first controllable output configured to apply an AC voltage across a first set of capacitively coupled electrodes that are positioned in a vicinity of the target region, so as to impose an electric field in the target region in a first direction and (ii) a second controllable output configured to apply an AC voltage across a second set of capacitively coupled electrodes that are positioned in the vicinity of the target region, so as to impose an electric field in the target region in a second direction; and

a controller configured to (a) control the first controllable output so that a first AC signal is generated for a first interval of time, the first AC signal having a first frequency and

a first amplitude, wherein the first frequency and the first amplitude are selected to impose an electric field that disrupts mitosis of the cancer cells, and (b) control the first controllable output so that a second AC signal is generated for a second interval of time, the second AC signal having a second frequency and a second amplitude, wherein the second frequency and the second amplitude are selected to impose an electric field that reduces motility of the cancer cells, and wherein the second amplitude is lower than the first amplitude, (c) control the second controllable output so that a third AC signal is generated for a third interval of time, the third AC signal having a third frequency and a third amplitude, wherein the third frequency and the third amplitude are selected to impose an electric field that disrupts mitosis of the cancer cells, and (d) control the second controllable output so that a fourth AC signal is generated for a fourth interval of time, the fourth AC signal having a fourth frequency and a fourth amplitude, wherein the fourth frequency and the fourth amplitude are selected to impose an electric field that reduces motility of the cancer cells, and wherein the fourth amplitude is lower than the third amplitude, and (e) continuously repeat (a) through (d) in an alternating sequence during a course of treatment.

22. The apparatus of claim 21, wherein the second amplitude is less than 75% of the first amplitude and wherein the fourth amplitude is less than 75% of the third amplitude.

23. The apparatus of claim 21, wherein the second frequency and the first frequency are different, and wherein the fourth frequency and the third frequency are different.

24. The apparatus of claim 21, wherein the second amplitude is less than 75% of the first amplitude and wherein the fourth amplitude is less than 75% of the third amplitude, wherein the second frequency and the first frequency are different, wherein the fourth frequency and

the third frequency are different, wherein the third frequency is the same as the first frequency, wherein the fourth frequency is the same as the second frequency, wherein the first interval of time is less than 5 seconds, wherein the second interval of time is less than 5 seconds, wherein the third interval of time is less than 5 seconds, and wherein the fourth interval of time is less than 5 seconds.

25. The apparatus of claim 21, wherein the first frequency is  $200 \text{ kHz} \pm 10\%$ , the second frequency is  $300 \text{ kHz} \pm 10\%$ , the third frequency is  $200 \text{ kHz} \pm 10\%$ , and the fourth frequency is  $300 \text{ kHz} \pm 10\%$ .

1/5




FIG. 1




FIG. 2A




FIG. 2B




FIG. 3




FIG. 4

3/5




FIG. 5




FIG. 6

4/5




FIG. 7




FIG. 8




FIG. 9A




FIG. 9B

# INTERNATIONAL SEARCH REPORT

International application No  
PCT/IB2017/051898

**A. CLASSIFICATION OF SUBJECT MATTER**  
INV. A61N1/32 A61N1/40  
ADD.

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)  
A61N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

EPO-Internal, WPI Data

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 2014/330268 A1 (PALTI YORAM [IL] ET AL) 6 November 2014 (2014-11-06) abstract; figures 11,12 paragraphs [0016] - [0024], [0063] -----	21-25
A	EP 1 933 937 A2 (NOVOCURE LTD [IL]) 25 June 2008 (2008-06-25) abstract; figures 1,2,5 paragraphs [0010] - [0016]; claims 1-20 -----	21-25
A	EP 1 502 623 A1 (KALACO SCIENT INC [US]) 2 February 2005 (2005-02-02) abstract; figure 2 the whole document ----- -/-	21-25



Further documents are listed in the continuation of Box C.



See patent family annex.

\* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance  
"E" earlier application or patent but published on or after the international filing date  
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)  
"O" document referring to an oral disclosure, use, exhibition or other means  
"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
31 May 2017	12/06/2017
Name and mailing address of the ISA/ European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Fax: (+31-70) 340-3016	Authorized officer  Pfeiffer, Uwe

## INTERNATIONAL SEARCH REPORT

International application No
PCT/IB2017/051898

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 6 278 895 B1 (BERNARD ROBERT M [US]) 21 August 2001 (2001-08-21) abstract; figures 17,18 the whole document -----	21-25
A	US 2003/191506 A1 (SHLOZNIKOV BORIS [CA]) 9 October 2003 (2003-10-09) the whole document -----	21-25
A	WO 2006/083625 A1 (CYBERONICS INC [US]; ARMSTRONG RANDOLPH K [US]; ARMSTRONG SCOTT A [US]) 10 August 2006 (2006-08-10) page 7, line 6 - line 26; figure 1A -----	21-25

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/IB2017/051898

### Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1.  Claims Nos.: **1-20**  
because they relate to subject matter not required to be searched by this Authority, namely:  
**Rule 39.1(iv) PCT - Method for treatment of the human or animal body by therapy**
2.  Claims Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3.  Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

### Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1.  As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2.  As all searchable claims could be searched without effort justifying an additional fees, this Authority did not invite payment of additional fees.
3.  As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4.  No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

#### Remark on Protest

The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.

The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.

No protest accompanied the payment of additional search fees.

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/IB2017/051898

Patent document cited in search report		Publication date		Patent family member(s)		Publication date
US 2014330268	A1	06-11-2014	CA	2911491 A1		13-11-2014
			CN	105530862 A		27-04-2016
			EP	2994045 A1		16-03-2016
			HK	1216596 A1		25-11-2016
			JP	2016529923 A		29-09-2016
			US	2014330268 A1		06-11-2014
			WO	2014181167 A1		13-11-2014
<hr/>						
EP 1933937	A2	25-06-2008	CA	2624624 A1		12-04-2007
			CN	101321555 A		10-12-2008
			CN	104771830 A		15-07-2015
			DK	1933937 T3		07-04-2015
			EP	1933937 A2		25-06-2008
			EP	2902075 A1		05-08-2015
			ES	2534488 T3		23-04-2015
			JP	2009520509 A		28-05-2009
			PT	1933937 E		23-04-2015
			US	2007225766 A1		27-09-2007
			US	2010324547 A1		23-12-2010
			WO	2007039799 A2		12-04-2007
<hr/>						
EP 1502623	A1	02-02-2005	CA	2434583 A1		08-01-2005
			DE	60317782 T2		30-10-2008
			EP	1502623 A1		02-02-2005
			ES	2297101 T3		01-05-2008
			TW	590762 B		11-06-2004
			US	2003158589 A1		21-08-2003
			ZA	200305749 B		28-07-2004
<hr/>						
US 6278895	B1	21-08-2001	AU	734611 B2		21-06-2001
			CA	2287366 A1		29-10-1998
			EP	0973579 A1		26-01-2000
			JP	2001522274 A		13-11-2001
			US	5873849 A		23-02-1999
			US	6278895 B1		21-08-2001
			WO	9847562 A1		29-10-1998
<hr/>						
US 2003191506	A1	09-10-2003	AT	311926 T		15-12-2005
			AU	5206901 A		30-10-2001
			AU	2001252069 B2		14-04-2005
			CA	2405867 A1		25-10-2001
			EA	200201085 A1		24-04-2003
			EP	1282457 A1		12-02-2003
			JP	2003530920 A		21-10-2003
			KR	20030003722 A		10-01-2003
			US	6546290 B1		08-04-2003
			US	2003191506 A1		09-10-2003
			WO	0178834 A1		25-10-2001
<hr/>						
WO 2006083625	A1	10-08-2006	CA	2595437 A1		10-08-2006
			EP	1843815 A1		17-10-2007
			US	2006173493 A1		03-08-2006
			WO	2006083625 A1		10-08-2006
<hr/>						